Chicago Partners Investment Group LLC Purchases Shares of 1,877 Charles River Laboratories International, Inc. $CRL

Chicago Partners Investment Group LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 1,877 shares of the medical research company’s stock, valued at approximately $315,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Brooklyn Investment Group boosted its stake in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. Cromwell Holdings LLC boosted its stake in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after acquiring an additional 152 shares in the last quarter. HM Payson & Co. bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth $31,000. Bayforest Capital Ltd bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth $63,000. Finally, Family Legacy Financial Solutions LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth $71,000. 98.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CRL has been the subject of several research reports. Wall Street Zen lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price objective for the stock from $142.00 to $195.00 in a research note on Tuesday, September 9th. Finally, William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $181.29.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $191.09 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $9.40 billion, a price-to-earnings ratio of -143.67, a P/E/G ratio of 5.01 and a beta of 1.50. The stock’s fifty day simple moving average is $163.61 and its 200-day simple moving average is $149.60.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the previous year, the company posted $2.80 earnings per share. Charles River Laboratories International’s revenue for the quarter was up .6% compared to the same quarter last year. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).